Entry 20
Probiotic science page
Uses gut adhesion and bifidogenic metabolites to reduce antibiotic-associated diarrhea and support infant gut development, with RCT evidence.
Overview
BB-12 is the world’s most documented probiotic Bifidobacterium strain. It has over 300 scientific publications and more than 130 clinical studies as of 2014 [1]. Chr. Hansen originally isolated it from dairy starter cultures. It has been used in infant formula, dietary supplements, and fermented foods since 1985 [1]. BB-12 is among the most thoroughly characterized probiotic strains for safety in preterm infants and immunocompromised populations [2,3].
Mechanism
Documented mechanisms for BB-12 include sticking to intestinal mucus and Caco-2 cells (a lab model of cells lining the gut). It excludes harmful gut bacteria. It strengthens the intestinal barrier by modulating tight junction proteins (proteins that seal gaps between gut cells). It tunes the immune system through interaction with toll-like receptors [1]. BB-12 survives gastrointestinal transit. It temporarily increases fecal bifidobacteria counts without permanently changing the native microbiota composition [1]. The strain resists gastric acid and bile salts. It produces short-chain fatty acids (fuel for gut cells), predominantly acetate, via the bifid shunt pathway [1].
Health Benefits
The Jungersen et al. (2014) comprehensive strain-specific review documents RCT evidence for several benefits. These include infant diarrhea prevention, antibiotic-associated diarrhea (AAD) risk reduction, respiratory tract infection reduction in infants, improved bowel function in constipation, and enhanced immune response to vaccination [1] [review citing multiple RCTs]. The PRIMAL multicenter phase III RCT (n=10,658 preterm infants across 59 NICUs) included BB-12 in a multi-strain formulation. It assessed gut dysbiosis (imbalance in gut bacteria) in preterm infants [2] [RCT, BB-12 in multi-strain context, PMID:39102225]. The strain is listed in the ESPGHAN position paper on probiotics for preterm infants [3] [position paper]. RCT evidence for constipation in adults and elderly populations is moderate [5] [narrative review]. Safety has been confirmed across multiple populations including neonates. No reports of systemic infection have been attributed to BB-12 [1].
Biology
Taxonomy: B. animalis subsp. lactis, following the Masco et al. (2004) reclassification from Bifidobacterium lactis to subspecies level within B. animalis [4]. It is Gram-positive, only grows without oxygen, non-motile, non-spore-forming, and irregular rod-shaped. It ferments carbohydrates via the bifid shunt (fructose-6-phosphate phosphoketolase pathway). This produces L(+)-lactate and acetate in a 3:2 molar ratio. The strain was originally isolated from dairy sources. It is acid and bile tolerant.
Bibliography
Jungersen M, Wind A, Johansen E, Christensen JE, Stuer-Lauridsen B, Eskesen D. (2014). The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12. Microorganisms. 2(2):92-110. PMID: 27682233
Van Rossum T, Haiss A, Knoll RL, MariBen J, Podlesny D, Pagel J, et al. (2024). Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial. JAMA Pediatr. 178(10):985-995. PMID: 39102225
van den Akker CHP, van Goudoever JB, Shamir R, Domellof M, Embleton ND, Hojsak I, et al. (2020). Probiotics and Preterm Infants: A Position Paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 70(5):664-680. PMID: 32332478
Masco L, Ventura M, Zink R, Huys G, Swings J. (2004). Polyphasic taxonomic analysis of Bifidobacterium animalis and Bifidobacterium lactis reveals relatedness at the subspecies level: reclassification of Bifidobacterium animalis as Bifidobacterium animalis subsp. animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium animalis subsp. lactis subsp. nov. Int J Syst Evol Microbiol. 54(Pt 4):1137-1143. PMID: 15280282
Salvatore S, Carlino M, Sestito S, Concolino D, Agosti M, Pensabene L. (2024). Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. Nutrients. 16(3):349. PMID: 38337634
Available Products
Chr. Hansen supplies BB-12 as a frozen or freeze-dried concentrate (BB-12 Probio-Tec) to manufacturers worldwide. It is used in hundreds of commercial products. These include infant formulas (Nestle, Mead Johnson), dietary supplement capsules and chewables (numerous brands), yogurts and fermented milks (various dairy companies), and hospital probiotic formulations [1].